Phytomedicine and Molecular Toxicology Research Laboratory, Department of Biochemistry, Federal University Oye-Ekiti, PMB 373, Oye-Ekiti, 371104, Nigeria.
Institute of Drug Research and Development, SE Bogoro Center, Afe Babalola University, PMB 5454, Ado-Ekiti, 360001, Nigeria.
Mol Biol Rep. 2022 Sep;49(9):8391-8400. doi: 10.1007/s11033-022-07657-x. Epub 2022 Jun 27.
This study assessed the hepatoprotective potential of flavonoid-rich extracts from Gongronema latifolium Benth on diabetes-induced type 2 rats via Fetuin-A and tumor necrosis factor-alpha (TnF-α).
In a standard procedure, the flavonoid-rich extract was prepared. For experimental rats, streptozotocin was injected intraperitoneally (45 mg/kg body weight) to induce diabetes mellitus. Following this, rats were given 5% of glucose water for 24 h. Hence, the animals were randomly divided into five groups of ten rats each, consisting of non-diabetic rats, diabetic controls, diabetic rats treated with low and high doses of flavonoid rich-extracts from Gongronema latifolium leaf (FREGL) (13 and 26 mg/kg, respectively), and diabetic rats treated with 200 mg/kg of metformin glibenclamide orally for 3 weeks. Afterwards, the animals were sacrificed, blood and liver were harvested to evaluate different biochemical parameters, hepatic gene expressions and histological examinations.
The results revealed that FREGL (especially at the low dose) significantly (p < 0.05) reduced alanine transaminase (ALT), aspartate aminotransferase (AST) and alkaline phosphate (ALP) activities, lipid peroxidation level, as well as relative gene expressions of fetuin-A and TNF-α in diabetic rats. Furthermore, diabetic rats given various doses of FREGL showed an increase in antioxidant enzymes and hexokinase activity, as well as glucose transporters (GLUT 2 and GLUT 4), and glycogen levels. In addition, histoarchitecture of the liver of diabetic rats administered FREGL (especially at the low dose) was also ameliorated.
Hence, FREGL (particularly at a low dose) may play a substantial role in mitigating the hepatopathy complication associated with diabetes mellitus.
本研究通过胎球蛋白-A 和肿瘤坏死因子-α（TnF-α）评估了从 Gongronema latifolium Benth 中提取的富含类黄酮的提取物对糖尿病诱导的 2 型大鼠的保肝作用。
按照标准程序制备富含类黄酮的提取物。对于实验大鼠，通过腹腔内注射链脲佐菌素（45mg/kg 体重）来诱导糖尿病。之后，大鼠给予 5%的葡萄糖水 24 小时。因此，将动物随机分为五组，每组 10 只非糖尿病大鼠、糖尿病对照组、分别用低剂量（13mg/kg）和高剂量（26mg/kg）Gongronema latifolium 叶富含类黄酮提取物（FREGL）治疗的糖尿病大鼠和用 200mg/kg 二甲双胍格列本脲口服治疗 3 周的糖尿病大鼠。之后，处死动物，采集血液和肝脏，评估不同的生化参数、肝基因表达和组织学检查。
结果表明，FREGL（尤其是低剂量）显著（p<0.05）降低了糖尿病大鼠的丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）和碱性磷酸酶（ALP）活性、脂质过氧化水平以及胎球蛋白-A 和 TNF-α的相对基因表达。此外，给予不同剂量 FREGL 的糖尿病大鼠表现出抗氧化酶和己糖激酶活性增加、葡萄糖转运体（GLUT2 和 GLUT4）和糖原水平增加。此外，给予 FREGL（尤其是低剂量）的糖尿病大鼠的肝组织形态学也得到改善。
因此，FREGL（特别是低剂量）可能在减轻糖尿病相关的肝病并发症方面发挥重要作用。
